The International Society of Pharmaceutical Engineering (ISPE) is field-testing the design principles of a comprehensive, industry-led program of self-evaluation of pharmaceutical quality that will align with the purpose of FDA’s quality metrics.
The International Society of Pharmaceutical Engineering (ISPE) announced at its 2018 ISPE Quality Manufacturing Conference that it is field-testing the design principles of a comprehensive industry-led program of self-evaluation of pharmaceutical quality program with industry colleagues, senior leaders, and regulators. The vision for the program is to evolve the focus from submission of harmonized quality metrics as given in recent FDA guidance documents to establishing a framework for advancing the state of pharmaceutical quality, while at the same time continuing to align with the purpose outlined by FDA. ISPE believes this approach will deliver on the objectives outlined by FDA and will increase the value to industry, ISPE said in a June 5, 2018 press release.
The “assess and aspire” framework provides methodologies and examples of key performance/business indicators for self-analysis and benchmarking of quality maturity, based on integration of culture, quality, and operational excellence disciplines, ISPE explained in the press release. Elements included in the framework are derived from International Council for Harmonization (ICH) Q10, Pharmaceutical Quality System. An organization may then choose to aspire to make improvements using the methodologies suggested.
ISPE’s Advancing Pharmaceutical Quality (APQ) program has established the following guiding principles:
• Demonstrate value to industry, regulators, and patients
• Industry for industry-at least at the outset
• Voluntary
• Be applicable across all sectors of the pharmaceutical industry
• Use company data and sites procedures “as is” to the extent possible to minimize additional work
• Leverage existing methodologies and program principles where relevant
• Complement existing FDA initiatives
• Simple/well-defined assessment criteria
• Phased approach
• Inclusion of incentives/recognition.
Goals of this program include:
• Enable and foster industry ownership of quality beyond compliance
• Integrate quality, cultural, and operational excellence principles and learnings
• Support and incentivize continual improvement
• Promote efficient use of resources by improving execution
• Increase reliability of supply of quality product
• Fuel benchmarking, sharing, and learning among companies
• Encourage self-improvement and supplier improvement
• Have a potential competitive advantage.
This program will use other similar programs such as the OSHA Voluntary Protection Program (VPP) as a basis. An overarching aspiration is that regulators will provide input to the design and may incorporate framework elements and learnings into regulatory programs.
Source: ISPE
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.